Last reviewed 2026-04-23 · How we verify

Placebo (for nortriptyline)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phase 3 active Small molecule

Placebo (for nortriptyline) is a Small molecule drug developed by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is currently in Phase 3 development for Control arm in nortriptyline phase 3 clinical trial.

Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline therapeutic response independent of drug action.

Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline therapeutic response independent of drug action. Used for Control arm in nortriptyline phase 3 clinical trial.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Placebo (for nortriptyline)
Sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Modality	Small molecule
Therapeutic area	Psychiatry/Neurology
Phase	Phase 3

Mechanism of action

Placebo is a non-active substance administered in controlled trials to establish a baseline for comparison against the active drug being tested. Any therapeutic benefit observed in placebo recipients is attributed to natural disease progression, regression to the mean, or psychological/expectancy effects. This allows researchers to isolate the true pharmacological efficacy of the investigational drug (nortriptyline in this case) by subtracting placebo response rates from active treatment response rates.

Approved indications

Control arm in nortriptyline phase 3 clinical trial

Common side effects

Placebo response (symptom improvement without active drug)

Key clinical trials

Procedural Framing and Epidural Steroid Injection Outcomes (NA)
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (PHASE2)
Pediatric Concussion Outcomes (PHASE4)
Nortriptyline for the Treatment of Functional Dyspepsia (PHASE3)
Treatment of Meniere's Disease With Migraine Medications (PHASE4)
Antidepressants Trial in Parkinson's Disease (PHASE3)
Treatment of Tinnitus With Migraine Medications (PHASE4)
Nortriptyline for Idiopathic Gastroparesis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo (for nortriptyline) CI brief — competitive landscape report
Placebo (for nortriptyline) updates RSS · CI watch RSS
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio CI

Frequently asked questions about Placebo (for nortriptyline)

What is Placebo (for nortriptyline)?

Placebo (for nortriptyline) is a Small molecule drug developed by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), indicated for Control arm in nortriptyline phase 3 clinical trial.

How does Placebo (for nortriptyline) work?

Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline therapeutic response independent of drug action.

What is Placebo (for nortriptyline) used for?

Placebo (for nortriptyline) is indicated for Control arm in nortriptyline phase 3 clinical trial.

Who makes Placebo (for nortriptyline)?

Placebo (for nortriptyline) is developed by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (see full National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline at /company/national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk).

What development phase is Placebo (for nortriptyline) in?

Placebo (for nortriptyline) is in Phase 3.

What are the side effects of Placebo (for nortriptyline)?

Common side effects of Placebo (for nortriptyline) include Placebo response (symptom improvement without active drug).

Manufacturer: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — full pipeline
Therapeutic area: All drugs in Psychiatry/Neurology
Indication: Drugs for Control arm in nortriptyline phase 3 clinical trial

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing